Celcuity (CELC) Leerink Global Healthcare Conference 2026 summary

Company overview and clinical development

• Developed a platform to quantify live tumor cell activity, identifying patients for targeted therapies.

• Focused on gedatolisib, a pan-PI3K/mTOR inhibitor, with completed and ongoing Phase III studies in breast cancer and early phase studies in prostate cancer.

• Early data show gedatolisib's efficacy in both treatment-naive and late-line breast cancer settings, regardless of PIK3CA mutation status.

Clinical data and competitive landscape

• Phase III data in second-line breast cancer showed a 9.3-month median PFS for gedatolisib combinations, a 7.3-month improvement over control, with a hazard ratio of 0.24.

• Early phase data in PIK3CA mutant patients showed 14.5 months median PFS; 10 months would be statistically significant versus current standards.

• Phase Ib reanalysis in mutation-positive patients showed up to 19 months median PFS, though with small sample size.

• Frontline Phase III study targets endocrine-resistant, HR-positive breast cancer, with safety run-in results and design updates expected soon.

• Early results in treatment-naive patients showed 48 months median PFS and 79% objective response rate.

Commercialization and market strategy

• Organizational build-out nearly complete, with sales force hiring planned for Q2 and targeting a mid-July approval date.

• Benchmarking suggests a sales force of around 90, similar to other breast cancer drug launches.

• IV administration aligns with current practice patterns and is seen as favorable for reimbursement and market access.

• Commercial assessments indicate strong physician preference for gedatolisib, with IV formulation not seen as a barrier.